SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation

Cranage, MP; Fraser, CA; Cope, A; McKay, PF; Seaman, MS; Cole, T; Mahmoud, AN; Hall, J; Giles, E; Voss, G; et al. Cranage, MP; Fraser, CA; Cope, A; McKay, PF; Seaman, MS; Cole, T; Mahmoud, AN; Hall, J; Giles, E; Voss, G; Page, M; Almond, N; Shattock, RJ (2011) Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. VACCINE, 29 (7). 1421 - 1430. ISSN 0264-410X https://doi.org/10.1016/j.vaccine.2010.12.034
SGUL Authors: Cope, Alethea Victoria Cranage, Martin Patrick Shattock, Robin John

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (662kB) | Preview

Abstract

Optimum strategies to elicit and maintain antibodies at mucosal portals of virus entry are critical for the development of vaccines against human immunodeficiency virus (HIV). Here we show in non-human primates that a novel regimen of repeated intravaginal delivery of a non-adjuvanted, soluble recombinant trimeric HIV-1CN54 clade C envelope glycoprotein (gp140) administered in Carbopol gel can prime for B-cell responses even in the absence of seroconversion. Following 3 cycles of repeated intravaginal administration, throughout each intermenses interval, 3 of 4 macaques produced or boosted systemic and mucosally-detected antibodies upon intramuscular immunisation with gp140 formulated in AS01 adjuvant. Reciprocally, a single intramuscular immunisation primed 3 of 4 macaques for antibody boosting after a single cycle of intravaginal immunisation. Virus neutralising activity was detected against clade C and clade B HIV-1 envelopes but was restricted to highly neutralisation sensitive pseudoviruses.

Item Type: Article
Additional Information: © 2010 Elsevier Ltd. Under a Creative Commons license (CC-BY 3.0)
Keywords: AIDS Vaccines, Adjuvants, Immunologic, Administration, Intravaginal, Animals, Antibodies, Neutralizing, Antibody Formation, Female, HIV Antibodies, HIV Infections, HIV-1, Immunity, Mucosal, Immunization, Secondary, Injections, Intramuscular, Macaca fascicularis, Neutralization Tests, Polyvinyls, Vagina, env Gene Products, Human Immunodeficiency Virus, Science & Technology, Life Sciences & Biomedicine, Immunology, Medicine, Research & Experimental, Research & Experimental Medicine, Immunisation, HIV-gp140, HUMAN-IMMUNODEFICIENCY-VIRUS, NEUTRALIZING ANTIBODIES, HIV-1 VACCINE, SECRETING CELLS, VAGINAL TRANSMISSION, CERVICAL SECRETIONS, RECOMBINANT GP120, IMMUNE-RESPONSE, MENSTRUAL-CYCLE, CHIMERIC VIRUS
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: VACCINE
ISSN: 0264-410X
Related URLs:
Dates:
DateEvent
4 February 2011Published
Web of Science ID: WOS:000287777500011
Download EPMC Full text (HTML)
URI: https://openaccess.sgul.ac.uk/id/eprint/848
Publisher's version: https://doi.org/10.1016/j.vaccine.2010.12.034

Actions (login required)

Edit Item Edit Item